These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 1676729)

  • 1. Cardiovascular and antiarrhythmic effects of esmolol in children.
    Trippel DL; Wiest DB; Gillette PC
    J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
    Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
    Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
    Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
    J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.
    Byrd RC; Sung RJ; Marks J; Parmley WW
    J Am Coll Cardiol; 1984 Feb; 3(2 Pt 1):394-9. PubMed ID: 6141193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
    Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
    Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
    Ko WJ; Chu SH
    J Am Coll Cardiol; 1994 Feb; 23(2):302-6. PubMed ID: 7905013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esmolol in the treatment of supraventricular tachyarrhythmias.
    Das G; Ferris J
    Can J Cardiol; 1988 May; 4(4):177-80. PubMed ID: 2899451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias.
    Adamson PC; Rhodes LA; Saul JP; Dick M; Epstein MR; Moate P; Boston R; Schreiner MS
    Pediatr Cardiol; 2006; 27(4):420-7. PubMed ID: 16835806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of tachycardia and hypertension following coronary artery bypass graft surgery: efficacy and haemodynamic effects of esmolol.
    Tempe DK; Mulchandani P; Tandon MS; Mehta N; Tomar AS; Banerjee A; Khanna SK
    Indian Heart J; 1999; 51(3):294-300. PubMed ID: 10624069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.
    Das G; Tschida V; Gray R; Dhurandhar R; Lester R; McGrew F; Askenazi J; Kaplan K; Emanuele M; Turlapaty P
    J Clin Pharmacol; 1988 Aug; 28(8):746-50. PubMed ID: 2905710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
    Reilly CS; Wood M; Koshakji RP; Wood AJ
    Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic esmolol infusion for the control of cardiovascular responses to extubation after intracranial surgery.
    Lim SH; Chin NM; Tai HY; Wong M; Lin TK
    Ann Acad Med Singap; 2000 Jul; 29(4):447-51. PubMed ID: 11056773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiology of esmolol.
    Greenspan AM; Spielman SR; Horowitz LN; Senior S; Steck J; Laddu A
    Am J Cardiol; 1985 Oct; 56(11):19F-26F. PubMed ID: 2864844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
    Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
    Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
    Cuneo BF; Zales VR; Blahunka PC; Benson DW
    Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The electrophysiologic properties of esmolol, a short acting beta-blocker.
    Greenspan AM; Spielman SR; Horowitz LN; Laddu A; Senior S
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):209-16. PubMed ID: 2900217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.